Literature DB >> 28757715

Outbreak of multidrug-resistant tuberculosis in an aboriginal family in eastern Taiwan.

Tao Qian Tang1, Ser-Chen Fu2, Ying-Huei Chen3, Shun-Tien Chien4, Jen-Jyh Lee1,5, Chih-Bin Lin1,5.   

Abstract

Spread of multidrug-resistant tuberculosis (MDR-TB) strains in the general population presents a serious threat to public health and severely threatens existing control efforts. Techniques such as spoligotyping and Mycobacterium interspersed repetitive units-variable-number tandem-repeat typing of mycobacterial isolates have been employed to confirm familial outbreaks of MDR-TB. We diagnosed and traced four MDR-TB cases in a family via genotyping. Despite aggressive treatment, the index case remained culture positive, but the other patients were cured. This is the first documentation of a familial MDR-TB outbreak affecting human immunodeficiency virus-seronegative patients in eastern Taiwan. Molecular techniques are important in the identification of sources of MDR-TB infections. The adult index case in our study developed MDR-TB due to poor compliance with the drug regimen (acquired resistance), followed by transmission of MDR-TB to his children in close household contact. This emphasizes the importance of an effective drug delivery program, such as directly observed treatment, to improve drug compliance and prevent the emergence of drug-resistant cases.

Entities:  

Keywords:  Aboriginal family; Multidrug-resistant tuberculosis; Mycobacterium interspersed repetitive units—variable-number tandem repeat; Outbreak; Spoligotyping; Taiwan

Year:  2014        PMID: 28757715      PMCID: PMC5509175          DOI: 10.1016/j.tcmj.2014.09.001

Source DB:  PubMed          Journal:  Ci Ji Yi Xue Za Zhi


1. Introduction

The World Health Organization estimated that the incidence of multidrug-resistant tuberculosis (MDR-TB), defined as isolates with resistance to at least isoniazid and rifampicin, was 220,000–400,000 cases (best estimate, 310,000) in the year 2011. MDR-TB has become an important issue in the management of TB [1]. The spread of MDR-TB strains in the general population presents a serious threat to public health and severely threatens existing control efforts, because the treatment of MDR-TB is prolonged (18–24 months), less efficacious (success rate <60%), more toxic, and much costlier [2] than that of drug-susceptible tuberculosis. MDR-TB can result from new transmission of a resistant strain (primary transmission) or poor management of a patient infected with drug-susceptible organisms (acquired resistance). Outbreaks of MDR-TB have occurred in health care facilities and institutional settings, primarily involving patients infected with the human immunodeficiency virus (HIV) [345]. A combination of epidemiologic investigation and genotyping has been used to find the origin of outbreaks and track dissemination of MDR-TB strains. In this report, we describe four HIV-seronegative MDR-TB cases in an aboriginal family in eastern Taiwan.

2. Case Reports

2.1. Case 1

The index case (Case 1) was an aboriginal man who was a tunnel worker. He lived in the village of Wan-Rong, Taiwan which had a TB incidence of 512.5 cases per population of 100,000 in 2006. He was first diagnosed with pulmonary TB in November 2000, when he was 43 years old. Sputum smears were positive for acid-fast bacilli, and sputum cultures grew Mycobacterium tuberculosis. This isolate was sensitive to all first-line drugs. The patient was cured after 8 months of standardized treatment, but due to a relapse in February 2002, antituberculosis treatment was restarted. During the second treatment course, the patient showed poor compliance with the treatment regimen. Sputum cultures were again positive in April 2004, and chest radiography revealed worsening of left lung infiltrations and cavitations (Fig. 1A). The results of a drug-susceptibility test (DST) of the sputum culture 2 months later revealed resistance to isoniazid (H) and rifampicin (R), so the patient's regimen was changed to ethambutol (E), pyrazinamide (Z), streptomycin (S), prothionamide (Pto), and moxifloxacin (Mfx). In September 2005, sputum cultures still grew M. tuberculosis, and repeated DST showed resistance to HERS.
Fig. 1

Chest radiographs of four patients with multidrug-resistant tuberculosis: (A) Case 1, (B) Case 2, (C) Case 3, and (D) Case 4.

Chest radiographs of four patients with multidrug-resistant tuberculosis: (A) Case 1, (B) Case 2, (C) Case 3, and (D) Case 4. The patient was enrolled in a directly observed therapy program (DOT-plus) in 2007, and continued treatment with E, Z, Pto, Mfx, para-aminosalicylic acid, and rifabutin (Rfb). However, this sputum cultures remained positive. Despite the use of Group I—V antitu- berculosis drugs, the patient's sputum cultures remained positive at the time of this report. He was diagnosed to have chronic MDR- TB in 2009 and was placed in long-term isolation in a negative- pressure room.

2.2. Case 2

Case 2 is the third daughter of the index case. In 2002, she was diagnosed with pulmonary TB at the age of 19 years. At that time, the isolated strain was sensitive to HERS. She completed 8 months of treatment with HERZ and was cured in June 2003. However, in November 2006, a follow-up chest radiograph (Fig. 1B) and sputum cultures confirmed recurrent disease. DST showed resistance to HR, so she was treated with E, Z, S, Pto, and Mfx. Streptomycin was used for 6 months, and she completed an 18-month treatment course and was cured in September 2008.

2.3. Case 3

Case 3 is the index patient's older son. He was diagnosed with pulmonary TB in May 2005, at the age of 14 years, during a regular health checkup. A chest radiograph revealed infiltrations in the left upper lobe (Fig. 1C). He was treated with HERZS, but 2 months later DST showed HER resistance. The regimen was switched to Z, S, Pto, Rfb, and Mfx. Streptomycin was used for 7 months. He completed 18 months of treatment and was cured in January 2007.

2.4. Case 4

Case 4 is the index patient's younger son. He was first diagnosed in November 2006, at the age of 13 years. A chest radiograph revealed infiltrations and cavitations over the left upper lobe (Fig. 1D). The first M. tuberculosis isolate was fully drug susceptible, and he was treated with HERZ. However, due to persistent positive sputum cultures 3 months after starting treatment, DST was repeated and revealed resistance to HERS. The regimen was switched to Z, kanamycin, para-aminosalicylic acid, Pto, Rfb, and Mfx. He was cured in March 2009 after sputum conversion for 18 months. All four patients were tested for antibodies to HIV by enzyme immunoassay, and all were found to be negative (Fig. 2).
Fig. 2

Pedigree of MDR-TB family. MDR-TB = multidrug-resistant tuberculosis.

Pedigree of MDR-TB family. MDR-TB = multidrug-resistant tuberculosis. Drug susceptibility testing was performed by the indirect proportion method. M. tuberculosis isolated from all four patients revealed similar multiple drug resistance to first-line HER and second-line ofloxacin. Fortunately, the strains were sensitive to kanamycin (Table 1). Isolates of MDR-TB stains from the four patients showed identical genotypes indistinguishable from each other by spoligotyping and Mycobacterium interspersed repetitive units—variable-number tandem-repeat (MIRU-VNTR) typing (Table 2).
Table 1

DST of strains of four patients.

CaseDateHRifESmKmPtoPASOfxCmRifabutin
1Nov 25, 2006RRRRSSSRSR
2Nov 17, 2006RRRSSRSRSR
3Nov 17, 2006RRRSSSSRSR
4May 17, 2006RRRRSSSRSR

Cm = capreomycin; DST = drug-susceptibility test; E = ethambutol; H = isoniazid; Km = kanamycin; Ofx = ofloxacin; Pto = prothionamide; R = resistant; R = Rif; S = susceptible; Sm = streptomycin.

Table 2

Genotyping results of strains of four patients.

CaseSpoligotypeMIRU-VNTR

MT01MT02MT03MT04MT05MT06MT07MT08MT09MT10MT11MT12MT13MT14MT15MT16MT17MT18MT19MT20MT21MT22MT23MT24
1Beijing2723323444446311253213423
2Beijing2723323444446311253213423
3Beijing2723323444446311253213423
4Beijing2723323444446311253213423

MIRU-VNTR = Mycobacterium interspersed repetitive units—variable-number tandem repeat.

DST of strains of four patients. Cm = capreomycin; DST = drug-susceptibility test; E = ethambutol; H = isoniazid; Km = kanamycin; Ofx = ofloxacin; Pto = prothionamide; R = resistant; R = Rif; S = susceptible; Sm = streptomycin. Genotyping results of strains of four patients. MIRU-VNTR = Mycobacterium interspersed repetitive units—variable-number tandem repeat.

3. Discussion

The household transmission in this family was proved by identical spoligotyping and MIRU-VNTR typing. The MDR-TB outbreak outlined in this study shows the potential of molecular epidemiology and field epidemiology in illustrating the sequence of transmission in clusters of MDR-TB. In the early 1950s, investigators reported that isoniazid-resistant strains of M. tuberculosis lacked catalase activity and were less virulent in guinea pigs and mice [678910] than susceptible strains. It was hypothesized that drug-resistant strains of M. tuberculosis might be less capable of being transmitted and less likely to produce secondary cases compared with drug-susceptible strains [9]. However, observations by Snider et al [10] suggested that the population in contact with MDR-TB bacilli developed the disease at the same rate as those in contact with drug-susceptible bacilli. More recently in Brazil, Teixeira et al [11] found that transmission and development of TB were comparable between household contacts with MDR-TB and those with drug-susceptible TB. In South Africa, Schaaf et al [12] examined the prevalence of PPD reactivity and active TB in children, and concluded that the incidence of infection and disease in children in contact with MDR-TB adult index cases was comparable with that occurring in children in contact with drug- susceptible adult index cases. Our report confirmed the household transmission of MDR-TB infection from an adult index case to his three children. The MDR-TB genotypes from all four patients belonged to the Beijing family. Beijing family genotypes of M. tuberculosis were first recognized in 1995. This family of strains accounted for 86% of tuberculosis isolates collected from Beijing, China [13], and it has spread worldwide. In 2005, Jou et al [14] reported that 187 of 421 M. tuberculosis isolates (44.4%) collected randomly in four geographic regions of Taiwan belonged to Beijing family genotypes. Antituberculosis drug resistance has been found more often in Beijing family genotype strains (46.4%) than in non-Beijing family genotype strains (34.4%). A countrywide study in Estonia also showed a strong correlation between the Beijing family and drug resistance. The Beijing family accounted for 87.5% of all MDR-TB isolates and 67.2% of all isolates with any drug resistance [15]. Some strains of the Beijing family have been demonstrated to have high virulence and were associated with active transmission young people who had BCG immunizations in Vietnam [16]. The adult index case in our study developed MDR-TB due to poor compliance with the drug regimen (acquired resistance), followed by transmission of MDR-TB to his children in close household contact (primary transmission). This emphasizes the importance of an effective drug delivery program such as DOT to improve drug compliance and prevent the emergence of drug-resistant cases. In addition, the prolonged infectious period of the index case increased the risk of household transmission. Timely diagnosis of MDR-TB and effective patient-centered treatment would help prevent transmission of MDR-TB in families and communities. In recent years, several fingerprinting methods for typing mycobacteria isolates have become available. The most widely used molecular methods for M. tuberculosis isolates are IS6110 restriction fragment length polymorphism (RFLP) typing, spoligotyping, and MIRU-VNTR typing. IS6110 RFLP typing of M. tuberculosis has been the gold standard for genotyping. However, it is laborious, time consuming, and expensive. The optimized MIRU-VNTR set combined with spoligotyping showed a slightly higher predictive value for the study of TB transmission than the current gold standard IS6110 RFLP [17]. Spoligotyping combined with MIRU-VNTR is less labor intensive than IS6110 RFLP. Because of its rapidity and ease of data exchange and comparison, this method has the potential to replace RFLP as the gold standard, and can help facilitate research and international comparisons in the molecular epidemiology of TB. Early detection and appropriate treatment of MDR-TB can result in a favorable response. Although the three children of the index case were infected with the same MDR-TB strain, their cases were detected early and they were compliant with treatment with second-line medications. Noncompliance of the index case resulted in the occurrence of MDR-TB, and he failed to show conversion even after years of treatment with second-line drugs. He is now under forced isolation for the rest of his life in a negative pressure setting. This serves as a solemn reminder of the importance of early detection and medical compliance. In summary, to our knowledge, this is the first documentation of a familial MDR-TB outbreak affecting HIV-seronegative patients in eastern Taiwan.
  15 in total

1.  Tubercle bacilli resistant to isoniazid: virulence and response to treatment with isoniazid in guinea-pigs and mice.

Authors:  M BARNETT; S R BUSBY; D A MITCHISON
Journal:  Br J Exp Pathol       Date:  1953-10

2.  Some observations on the pathogenicity of isoniazid-resistant variants of tubercle bacilli.

Authors:  G MIDDLEBROOK; M L COHN
Journal:  Science       Date:  1953-09-11       Impact factor: 47.728

3.  Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis.

Authors:  Neel R Gandhi; Paul Nunn; Keertan Dheda; H Simon Schaaf; Matteo Zignol; Dick van Soolingen; Paul Jensen; Jaime Bayona
Journal:  Lancet       Date:  2010-05-22       Impact factor: 79.321

4.  Evaluation of young children in contact with adult multidrug-resistant pulmonary tuberculosis: a 30-month follow-up.

Authors:  H Simon Schaaf; Robert P Gie; Magdalene Kennedy; Nulda Beyers; Peter B Hesseling; Peter R Donald
Journal:  Pediatrics       Date:  2002-05       Impact factor: 7.124

5.  Spread of drug-resistant pulmonary tuberculosis in Estonia.

Authors:  A Krüüner; S E Hoffner; H Sillastu; M Danilovits; K Levina; S B Svenson; S Ghebremichael; T Koivula; G Källenius
Journal:  J Clin Microbiol       Date:  2001-09       Impact factor: 5.948

6.  Distribution of the Beijing family genotypes of Mycobacterium tuberculosis in Taiwan.

Authors:  Ruwen Jou; Chen-Yuan Chiang; Wei-Lun Huang
Journal:  J Clin Microbiol       Date:  2005-01       Impact factor: 5.948

7.  Predominance of a single genotype of Mycobacterium tuberculosis in countries of east Asia.

Authors:  D van Soolingen; L Qian; P E de Haas; J T Douglas; H Traore; F Portaels; H Z Qing; D Enkhsaikan; P Nymadawa; J D van Embden
Journal:  J Clin Microbiol       Date:  1995-12       Impact factor: 5.948

8.  Outbreak of multi-drug-resistant tuberculosis in a New York State prison, 1991.

Authors:  S E Valway; S B Richards; J Kovacovich; R B Greifinger; J T Crawford; S W Dooley
Journal:  Am J Epidemiol       Date:  1994-07-15       Impact factor: 4.897

9.  Infection and disease among contacts of tuberculosis cases with drug-resistant and drug-susceptible bacilli.

Authors:  D E Snider; G D Kelly; G M Cauthen; N J Thompson; J O Kilburn
Journal:  Am Rev Respir Dis       Date:  1985-07

10.  Hospital outbreak of multidrug-resistant Mycobacterium tuberculosis infections. Factors in transmission to staff and HIV-infected patients.

Authors:  C Beck-Sagué; S W Dooley; M D Hutton; J Otten; A Breeden; J T Crawford; A E Pitchenik; C Woodley; G Cauthen; W R Jarvis
Journal:  JAMA       Date:  1992-09-09       Impact factor: 56.272

View more
  1 in total

1.  Transmission of multidrug-resistant tuberculosis within family households by DTM-PCR and MIRU-VNTR genotyping.

Authors:  Jun Chen; Lifeng Chen; Meng Zhou; Gang Wu; Fenglian Yi; Chen Jiang; Qionghong Duan; Meilan Zhou
Journal:  BMC Infect Dis       Date:  2022-02-26       Impact factor: 3.090

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.